Skinhealth Systems Inc

Skinhealth Systems Inc(SKIN)股票分析

$10.350

-0.655 (-6.33%)收盤時

Loading chart…
最高
11.675
開盤
11.580
成交量加權均價
10.75
成交量
23.07K
市值
234.90M
最低
10.228
成交金額
248.01K
企業價值/稅息折舊攤銷前利潤(TTM)
5.98

SkinHealth Systems Inc., formerly The Beauty Health Company, is a global medical aesthetics company. The Company, anchored by Hydrafacial, a professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp with Keravive, combines advanced device technology, proprietary consumables, and clinical validation to deliver treatment experiences through an omnichannel network of providers worldwide. Hydrafacial specializes in the category of hydradermabrasion with its patented delivery system that cleanses, extracts and hydrates the skin with proprietary solutions and serums. The treatment extends to the scalp through its HydraScalp powered by Keravive treatment, which is designed to support the hair's natural growth. SkinStylus specializes in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals.

AI 分析 of Skinhealth Systems Inc (SKIN)

持有

Currently, SKIN is not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $10.38, which is significantly below its 52-week high of $34.80, indicating a potential for recovery but also substantial risk. The RSI is at 44.91, suggesting it is near neutral territory, and the forward P/E ratio is extremely high at 106.38, indicating that the stock may be overvalued at this price. The main risk is the analyst downgrade from TD Cowen, which lowered its price target to $0.90, reflecting concerns about revenue and competition.

估值指標

Skinhealth Systems Inc(SKIN)目前預期本益比為 106.38,5 年平均預期本益比為 14.58。

預期本益比

合理
5 年均值 P/E
14.58
目前P/E
106.38
高估
162.12
低估
-132.96

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
25.64
目前EV/EBITDA
5.98
高估
63.30
低估
-12.03

預期股價營收比

合理
5 年均值 P/S
2.30
目前P/S
0.24
高估
4.99
低估
-0.40

Alphio AI 對 SKIN 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SKIN

$1.44

情境價格

基

基準

基準 · 50%SKIN

$1.26

情境價格

悲

悲觀

悲觀 · 25%SKIN

$1.05

情境價格

持有 SKIN 的大戶

L

Linden Advisors LP

+ 持有SKIN

+60.32%

3個月報酬率

事件時間軸

2026-11-05 (ET)

18:00:00

Company Raises FY26 EBITDA Outlook to $48M-$50M

18:00:00

SkinHealth Systems Reports Q3 Revenue of $69.2M

2026-10-13 (ET)

20:00:00

Beauty Health Co Trading Halted, News Pending

2026-10-01 (ET)

06:30:00

SkinHealth Systems Launches SkinStylus Device in Europe

2026-08-26 (ET)

09:30:00

SkinHealth Systems Launches Hydrafacial Impact Education Program

資訊

SKIN 常見問題 —— 由 Alphio AI 解答

SkinHealth Systems Inc., formerly The Beauty Health Company, is a global medical aesthetics company. The Company, anchored by Hydrafacial, a professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp with Keravive, combines advanced device technology, proprietary consumables, and clinical validation to deliver treatment experiences through an omnichannel network of providers worldwide. Hydrafacial specializes in the category of hydradermabrasion with its patented delivery system that cleanses, extracts and hydrates the skin with proprietary solutions and serums. The treatment extends to the scalp through its HydraScalp powered by Keravive treatment, which is designed to support the hair's natural growth. SkinStylus specializes in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals. It operates in the Consumer Non-Cyclicals sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, SKIN is not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $10.38, which is significantly below its 52-week high of $34.80, indicating a potential for recovery but also substantial risk. The RSI is at 44.91, suggesting it is near neutral territory, and the forward P/E ratio is extremely high at 106.38, indicating that the stock may be overvalued at this price. The main risk is the analyst downgrade from TD Cowen, which lowered its price target to $0.90, reflecting concerns about revenue and competition.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易